Table 1.
Radiation recall phenomenon after administration of SARS-CoV-2 vaccine
Report | Age | sex | Type of vaccine | Vaccinations | primary tumor | Tumor site | Radiation dose (to tumor) (Gy) | Time interval (end of radiotherapy to 1st vaccination) | Time to onset of skin reaction (final vaccination to skin reaction) | Severity of skin reaction |
---|---|---|---|---|---|---|---|---|---|---|
Soyfer V et al. | 68 | male | Pfizer-BioNTech (mRNA vaccine) | Twice | Unclassified spindle cell sarcoma | Back | 50 | 175 days | 5 days | Mild |
Soyfer V et al. | 64 | Male | Pfizer-BioNTech (mRNA vaccine) | Twice | Solitary fibrous tumor | Chest wall | 39 | 11 days | 6 days | Mild |
Afacan E et al. | 60 | Female | Sinopharm (inactivated virus vaccine) | Twice | Melanoma | Leg | 30 | 39 months | 5 days | Mild |
Stewart R et al. | 57 | Female | AstraZeneca (vector vaccine) | Once | Acinic cell carcinoma | Parotid gland | 66 | 6 months | 3 weeks | Mild |
Present case | 51 | Female | Moderna (mRNA vaccine) | Once | Invasive ductal carcinoma | Breast | 60 | 30 days | 7 days | Mild |